Gabapentin
Product Images NDC 63304-628

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63304-628). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ranbaxy Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Contain100 (Contain100)

Gabapentin Capsules USP 100 mg by Ranbaxy Pharmaceuticals Inc. The label indicates 100 capsules per container, for prescription use only (Rx only). It includes storage instructions, a barcode, and warnings to dispense the accompanying Medication Guide to each patient. The label also notes the product is packaged in a child-resistant container.*

FDA Label Image

300 mg Bottle Label (Contain300)

Gabapentin Capsules, USP 300 mg label from Ranbaxy Pharmaceuticals Inc. It indicates the package contains 100 capsules for prescription use only. The label provides dosage information, storage instructions, barcode, and manufacturer details from Ranbaxy Laboratories Limited, India.*

FDA Label Image

Contain400 (Contain400)

Gabapentin Capsules, USP 400 mg label from Ranbaxy Pharmaceuticals Inc. The label includes the NDC 63304-629-01, indicates a package of 100 capsules, and notes 'Rx only'. It also contains dispensing instructions and storage information. The label features the Ranbaxy logo and barcode.*

FDA Label Image

Figure 1 (Figure1)

A line graph depicting the mean pain score over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, while the y-axis shows the mean pain score from 0 to 10. Two study phases are noted: a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a consistent decrease in mean pain score over time, while placebo remains relatively stable. Statistical significance is indicated at multiple time points with p < 0.01.*

FDA Label Image

Figure 2 (Figure2)

A line graph showing Mean Pain Score over 7 weeks during a 3-week dose titration period followed by a 4-week fixed dose period. It compares placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, indicating pain scores decrease more with Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Figure3)

A bar graph showing the percentage of responders at endpoint in two studies comparing placebo (PBO) and Gabapentin (GBP) at various dosages. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers indicate p-values less than 0.01 and 0.001 for Gabapentin groups versus placebo.*

FDA Label Image

Figure 4 (Figure4)

A scatter plot showing percentage difference against daily dose (mg) for Gabapentin from three studies labeled a, b, and c. The x-axis displays daily doses at approximately 600, 900, 1200, and 1800 mg, while the y-axis represents percentage difference from 2% to 22%. Each study data point is differentiated by distinct markers in black, gray, and white.*

FDA Label Image

Mstructure (Mstructure)

Chemical structure of Gabapentin, showing a cyclohexane ring substituted with an aminomethyl group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.